Temozolomide for treatment of brain metastases: A review of 21 clinical trials

Table 1 Study characteristics of the studies that used temozolomide as a single agent

Trial	Publication information(author/yr/country)	Patient characteristic			Cancer	Prior treatment
		Total number	Median age	Gender (male/female)
1	Abrey et al[16]/2001/United States	41 (341)	60	11/30	NSCLC (n = 22)	WBRT (n = 41)
					Breast (n = 10)	Stereotactic RT (n = 9)
					Melanoma (n = 3)	Chemotherapy (n = 35)
					SCLC (n = 2)	Surgery (n = 11)
					Rectal (n = 2)
					Ovarian (n = 1)
					Endometrial (n = 1)
2	Siena et al[20]/2009/Italy	157	51.14/53.93/59.12	72/85	Melanoma (n = 53)	WBRT (n = 41)
					Breast cancer (n = 51)	Chemotherapy (n = 98)
					NSCLC (n = 53)	Radiotherapy (n = 34)
3	Schadendorf et al[21]/2006/Germany	45 (405/376)	54.5	29/16	Melanoma	Chemotherapy (n = 21)
4	Giorgio et al[19]/2005/Italy	30	65	23/7	NSCLC	WBRT (n = 30)
						Stereotactic radio surgery (n = 1)
						Chemotherapy (n = 30)
5	Christodoulou et al[17]/2000/Greece	28 (241)	56	19/9	NSCLC (n = 12)	WBRT (n = 23)
					SCLC (n = 5)	Radiation(other sites) (n = 5)
					Breast (n = 4)	Surgery (n = 4)
					Other (n = 7)	Chemotherapy (n = 22)
						Biologic therapy(n = 1)
6	Agarwala et al[15]/2004/United States	151 (1221)	537/46.58	95/56	Melanoma	Chemotherapy (n = 34)
						Immunotherapy (n = 237/218)
7	Dziadziuszko et al[18]/2003/Poland	12 (111)	57	6/6	NSCLC	WBRT (n = 4)
						Chemotherapy (n = 1)
						Surgery (NA)
						Radiotherapy (NA)

¹The number of patients eligible for the assessment of clinical outcomes;

²Non–small cell lung cancer (NSCLC);

³Breast cancer;

⁴Melanoma;

⁵The number of patients eligible for the assessment of brain lesion response;

⁶The number of patients eligible for the assessment of extracerebral response;

⁷No prior chemotherapy;

⁸Prior chemotherapy. NA: Not available; SCLC: Small cell lung cancer; WBRT: Whole-brain radiotherapy.